These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 32480349)

  • 1. Metabolic consequences of immune checkpoint inhibitors: A new challenge in clinical practice.
    Parthymos I; Liamis G; Dounousi E; Pentheroudakis G; Mauri D; Zarkavelis G; Florentin M
    Crit Rev Oncol Hematol; 2020 Jul; 151():102979. PubMed ID: 32480349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know).
    Ruggeri RM; Campennì A; Giuffrida G; Trimboli P; Giovanella L; Trimarchi F; Cannavò S
    J Endocrinol Invest; 2019 Jul; 42(7):745-756. PubMed ID: 30471004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System.
    Raschi E; Mazzarella A; Antonazzo IC; Bendinelli N; Forcesi E; Tuccori M; Moretti U; Poluzzi E; De Ponti F
    Target Oncol; 2019 Apr; 14(2):205-221. PubMed ID: 30927173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of Immune Checkpoint Inhibitor Toxicities: A Review and Clinical Guideline for Emergency Physicians.
    Hryniewicki AT; Wang C; Shatsky RA; Coyne CJ
    J Emerg Med; 2018 Oct; 55(4):489-502. PubMed ID: 30120013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy Toxicities.
    Sanchez K; Page DB; Urba W
    Surg Oncol Clin N Am; 2019 Jul; 28(3):387-401. PubMed ID: 31079795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese Adverse Drug Event Report database.
    Sato K; Mano T; Iwata A; Toda T
    J Neurooncol; 2019 Oct; 145(1):1-9. PubMed ID: 31452071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rheumatic immune related adverse events in patients treated with checkpoint inhibitors for immunotherapy of cancer.
    Sebastiani GD; Scirocco C; Galeazzi M
    Autoimmun Rev; 2019 Aug; 18(8):805-813. PubMed ID: 31176871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors.
    Weinmann SC; Pisetsky DS
    Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii59-vii67. PubMed ID: 31816080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endocrine immune-related adverse effects of immune-checkpoint inhibitors.
    Trevisani V; Iughetti L; Lucaccioni L; Predieri B
    Expert Rev Endocrinol Metab; 2023; 18(5):441-451. PubMed ID: 37682107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019).
    Majem M; García-Martínez E; Martinez M; Muñoz-Couselo E; Rodriguez-Abreu D; Alvarez R; Arance A; Berrocal A; de la Cruz-Merino L; Lopez-Martin JA
    Clin Transl Oncol; 2020 Feb; 22(2):213-222. PubMed ID: 31993963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint inhibitors and endocrine side effects, a narrative review.
    Agrawal L; Bacal A; Jain S; Singh V; Emanuele N; Emanuele M; Meah F
    Postgrad Med; 2020 Mar; 132(2):206-214. PubMed ID: 31876444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Check point inhibitors and autoimmunity: Why endocrinopathies and who is prone to?
    Percik R; Shoenfeld Y
    Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101411. PubMed ID: 32278687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.
    Martins F; Sofiya L; Sykiotis GP; Lamine F; Maillard M; Fraga M; Shabafrouz K; Ribi C; Cairoli A; Guex-Crosier Y; Kuntzer T; Michielin O; Peters S; Coukos G; Spertini F; Thompson JA; Obeid M
    Nat Rev Clin Oncol; 2019 Sep; 16(9):563-580. PubMed ID: 31092901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint inhibitor-induced sarcoidosis-like granulomas.
    Rambhia PH; Reichert B; Scott JF; Feneran AN; Kazakov JA; Honda K; Koon H; Gerstenblith MR
    Int J Clin Oncol; 2019 Oct; 24(10):1171-1181. PubMed ID: 31321613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunotherapy is cancer treatment with a novel side-effect profile].
    Kondrup M; Raunkilde L; Svane IM; Schmidt H; Bastholt L
    Ugeskr Laeger; 2017 Oct; 179(40):. PubMed ID: 28992844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders.
    Jannin A; Penel N; Ladsous M; Vantyghem MC; Do Cao C
    Crit Rev Oncol Hematol; 2019 Sep; 141():23-35. PubMed ID: 31202955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New oncologic emergencies: What is there to know about inmunotherapy and its potential side effects?
    Barquín-García A; Molina-Cerrillo J; Garrido P; Garcia-Palos D; Carrato A; Alonso-Gordoa T
    Eur J Intern Med; 2019 Aug; 66():1-8. PubMed ID: 31130304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endocrine sequelae of immune checkpoint inhibitors.
    Ntali G; Kassi E; Alevizaki M
    Hormones (Athens); 2017 Oct; 16(4):341-350. PubMed ID: 29518754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
    Sibaud V
    Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease: A Systematic Review.
    Abdel-Wahab N; Shah M; Lopez-Olivo MA; Suarez-Almazor ME
    Ann Intern Med; 2018 Jan; 168(2):121-130. PubMed ID: 29297009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.